| To accelerate development of safe drugs, we have expedited clinical trials by using innovative trial design, biomarkers and bridging methods. This has reduced patient exposure during trials as well as the duration of trials. |
| Generation of extensive in vitro and preclinical data has in certain instances provided solutions to seamless in vitro/in vivo correlation thus reducing the need for patient exposure. |
We continue to enhance our capabilities across the drug development team and
increase vigilance through clinical quality assurance. |
|
|
| One of the key initiatives undertaken in the reporting period: |
| Collaboration of Clinical Trials Teams: Collaboration and integration of various business units within Dr. Reddy's has generated a platform for shared success and has created a single point of knowledge base between Global Generics, Proprietary Products (PP), and Biologics clinical development. |
|
